Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Superluminal Medicines, Inc.

Clinicaltrial registered29 Oct 2026

Superluminal Medicines, Inc.

29 Oct 2026: Trial registered · A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
29 Oct 2026
Title
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Conditions
Healthy Participants
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07905560
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Superluminal Medicines, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Superluminal Medicines, Inc. in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.